Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern. The company presented the update during a webcast from the Alzheimer’s Association International Conference, where executives said [...]







